tbuckley/cabot-search huggingface dataset:
Reversal of Allergic Airway Hyperreactivity after Long-term Allergen Challenge Depends on T Cells
Authors: Z.-H. Cui
Journal: American Journal of Respiratory and Critical Care Medicine (2003)

Long-term allergen exposure can attenuate inflammation and revert airway hyperreactivity to normal responsiveness. A model of such reversal was established in which airway hyperreactivity and inflammation in ovalbumin-sensitized and challenged mice were decreased after multiple daily airway challenges. This change in responsiveness and inflammation was associated with a transition from a helper T cell Type 2 to a helper T cell Type 1 cytokine-biased profile in bronchoalveolar lavage fluid. Cell transfer from long-term exposed mice into hyperreactive mice also restored normal airway responsiveness, establishing the mechanism underlying the reversal of the hyperreactivity as active suppression, but did not affect eosinophilic airway inflammation. Conversely, airway hyperreactivity, suppressed as a result of long-term allergen exposure, could be reestablished by depleting γδ T cells, in particular Vγ4+ cells. Antigen-specific tolerance of αβ T cells or suppression by non-γδ T cells did not play a role in the reversal to normal airway responsiveness and γδ T cells did not play a role in the regulation of the allergic inflammatory response. These findings show that normal responsiveness in previously hyperreactive mice, achieved after long-term allergen challenge, is based on several, apparently independent regulatory mechanisms. One of these, focused on airway responsiveness, involves active suppression and requires γδ T cells.
Sympathetic joint effusion in septic arthritis
Authors: S. B. Baker
Journal: JAMA (1978)

SYMPATHETIC joint effusions have not received much attention in the rheumatologic literature; in fact, we have been unable to find a general discussion of this phenomenon. A sympathetic effusion may be defined as a transudative, noninflammatory synovial fluid in a joint adjacent to a site of inflammation. The clinical picture is that of an acute arthritis or periarthritis; with synoviocentesis, a noninflammatory fluid is found. A variety of diseases are associated with this combination, including sarcoidosis, erythema nodosum, calcific periarthritis, apatite arthritis, gout, systemic lupus erythematosus, hypertrophic pulmonary osteoarthropathy, and an acute arthritis associated with chronic hemodialysis. In these entities, the supposition is that the primary inflammatory process occurs adjacent to the joint, in the periarticular structures, and the synovial fluid represents a secondary or sympathetic response. A similar phenomenon can occur between two adjacent joints. In particular, a focus of sepsis in one joint can cause a sympathetic effusion
Hebdomadal Thyroxine
Authors: Isadore N. Rosenberg
Journal: New England Journal of Medicine (1969)

IN this issue of the Journal, Bernstein and Robbins report that 2.0 mg of L-thyroxine given orally as the sodium salt once a week provided satisfactory maintenance therapy for myxedema, and that this regimen effectively inhibited TSH secretion as judged by suppression of thyroid uptake of radioactive iodine in euthyroid persons. Because of the slowness with which circulating thyroxine is degraded (10 per cent per day), and because of its remarkably prolonged metabolic action (two to three months may elapse between discontinuation of thyroid feeding in myxedema and the decline in metabolic rate to the pretreatment value), it is . . .
Archives of Ophthalmology, Chicago
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hydronephrosis in infants and children. II. Surgical management and results
Authors: A. C. Uson
Journal: JAMA (1968)

From 1935 through 1965, 91 pyeloplasties and 45 nephrectomies were performed upon 126 infants or children with hydronephroses. In 27, nephrostomy was done before nephrectomy or pyeloplasty. Several children underwent unilateral nephrectomy and pyeloplasty on the opposite kidney; a few had bilateral pyeloplasties. Of the 126 children who underwent surgery for hydronephrosis, a total of 184 surgical procedures was necessary to excise or correct the hydronephrosis, as well as concomitant urological anomalies. "Splinting" catheters and nephrostomy or pyelostomy drainage tubes were used in almost all our pyeloplasties. The results of pyeloplasty have been good in children with grade 1 (mild) and grade 2 (moderate) hydronephrosis, and only fair in those with grade 3 (severe) hydronephrosis. Complications and failures occurred principally from 1935 to 1945. No surgical deaths, after pyeloplasty, ensued in the entire series.
JACQUES INAUDI, A MODERN PRODIGY.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Marriages
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1266: Co-expression of P-glycoprotein and ABCG2 in a cell line model reveals both independent and cooperative transporter function
Authors: Andrea Robinson, Robert Robey, Michael Gottesman
Journal: Cancer Research (2019)

Abstract Although overexpression of multiple ATP-binding cassette transporters has been reported in clinical samples, few studies have examined how expression of multiple transporters might confer resistance to chemotherapy drugs. We therefore examined how P-glycoprotein (P-gp, encoded by the ABCB1 gene) and ABCG2 contribute to drug resistance in a cell line model. HEK-293 cells were transfected with vector encoding full-length ABCB1, ABCG2, or a vector containing both genes under the control of a separate promoter. Cells transfected to express both transporters (B1/G2 cells) expressed high levels of both transporters and were able to transport both the P-gp-specific substrate rhodamine 123 and the ABCG2 specific substrate pheophorbide a when examined by flow cytometry. B1/G2 cells were also cross-resistant to the P-gp substrate doxorubicin, the ABCG2 substrate topotecan as well as mitoxantrone, a substrate of both transporters. The checkpoint inhibitor prexasertib was also found to be a substrate of both P-gp and ABCG2. When B1/G2 cells were incubated with both rhodamine 123 and pheophorbide a, transport of both compounds was observed, suggesting that P-gp and ABCG2 can function independently to transport substrates. P-gp and ABCG2 were also found to function cooperatively to transport the common fluorescent substrates mitoxantrone and BODIPY®-prazosin, as it was necessary to inhibit both transporters to prevent efflux from B1/G2 cells. This was also true in 3-day cytotoxicity assays with mitoxantrone and prexasertib. Thus, P-gp and ABCG2 can independently and cooperatively confer resistance to substrates, underscoring the need to inhibit multiple transporters when they are coexpressed. Citation Format: Andrea Robinson, Robert Robey, Michael Gottesman. Co-expression of P-glycoprotein and ABCG2 in a cell line model reveals both independent and cooperative transporter function [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1266.
NCCN News
Journal: Journal of the National Comprehensive Cancer Network (2019)

Support Application Through Epic's App OrchardFlatiron Health, a healthcare technology company focused on accelerating cancer research and improving patient care, announced the availability of its clinical decision support and pathways application, Flatiron Assist, in the App Orchard.Flatiron Assist supports oncologists in selecting therapies in line with best clinical practices, including the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), and in identifying potentially relevant clinical trials.The integrated regimen selection workflow allows clinicians to quickly confirm the clinical data needed to determine adherence to guidelines.Health system administrators can use the clinical data collected by this tool to streamline the prior authorization process, measure variation in care across a practice or health system, and report pathways compliance to payers."The rapidly evolving treatment landscape and increasing payer reporting requirements make it challenging for busy oncologists to efficiently get the best treatments to their patients," said James Hamrick, MD, Senior Medical Director, Flatiron Health."Flatiron Assist is an EHR-integrated tool that puts the doctor and the patient at the forefront, enabling evidence-based treatment selection, efficient payer authorization, and insight into care patterns across practices and health systems."Available in the App Orchard, Flatiron Assist is a SMART on FHIR application that will launch from the patient's chart in Epic, eliminating the need for duplicate data entry outside the electronic medical record.Flatiron Assist pulls available demographics, diagnosis, and cancer-specific data, such as staging, from Epic and, based on those inputs, surfaces evidence-based therapy options and clinical trials for each patient.Once the oncologist chooses a treatment regimen in Flatiron Assist, the selected regimen is automatically opened in Epic."Integrating NCCN's recommendations into point-of-care apps like Flatiron Assist puts the latest evidence and multidisciplinary expert knowledge at the fingertips of oncologists everywhere," said Robert W. Carlson, MD, Chief Executive Officer, NCCN."NCCN Guidelines are the most frequently updated medical guidelines in any discipline; they should also be the most accessible.The convenience of Flatiron Assist can give doctors more time to engage in shared decision making in order to determine which guideline-concordant treatment plan offers the most benefit."For more information on using Flatiron Assist, visit the App Orchard Marketplace, or contact flatironassist@flatiron.com.
Innovative On-call Methods Sought
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Asbestosis
Authors: Nicholas G. Demy
Journal: JAMA (1961)

<h3>To the Editor:—</h3> The editorial, "Dangerous Dusts and Furtive Fumes—'New' and Resurrected" (<i>JAMA</i>, Nov. 5, 1960, page 1320), is correct in pointing out an interesting illusion. A truly new disease has a classic description to which little can be added as time goes on, but the unwary reporter of a "new" disease who ignores classical literature, whether medical or not, is apt to be only a resurrection man. Asbestosis is so "new" a disease that industry has reluctantly accepted it as an occupational hazard. And yet Strabo, the Greek geographer and historian (63 B. C.—24 A. D.) described the dangers of asbestos weaving, and Pliny the Younger (61-113 A. D.), in his description of the diseases of slaves, called asbestosis an occupational disease. Both writers stated that the use of asbestos in the manufacture of handkerchiefs, headcloths, and tablecloths was common, and that the cost of these articles was equal
Transureteroureterostomy
Authors: Fletcher C. Derrick
Journal: JAMA (1967)

INJURY to the distal third of the ureter is not uncommon. It usually follows surgery of pelvic organs. If recognized at the time of surgery the primary repair can usually be done with good results. The late complications of ureteral stricture, ureterovaginal fistula, or ureteral necrosis and the leakage of urine either into the retroperitoneal or peritoneal spaces present more difficult problems. Numerous techniques for restoration of ureterovesical continuity have met with success. Primary ureteral anastomosis, primary reimplantation of the ureter into the bladder, bladder tube flaps, and interposition of isolated ileal segments have all been done and are accepted procedures. However, the amount of destroyed ureter sometimes does not allow one of these primary techniques, and ileal segment construction is a formidable procedure. The new technique presented here for management of injury to the distal portion of the ureter can be used as a primary means of repair at
Effect of lipid lowering therapy with atorvastatin alone or in association with different hormone replacement schemes in female patients with severe hypercholesterolemia Giuseppe M. C. Rosano, Giuseppe Mercuro, Filippo Leonardo, Sandra Zoncu, Massimo Fini. San Raffaele Hospital - Roma - Tosinvest Sanit�, Roma, Italy, University of Cagliari, Cagliari, Italy
Journal: Journal of the American College of Cardiology (2001)
Extracellular matrix remodeling at the early stages of liver regeneration in the rat
Authors: T Kim
Journal: Hepatology (1997)

Previous studies have shown that activity of urokinase-type plasminogen activator (u-PA) increases very rapidly (within 1 minute) after partial hepatectomy. In view of the well-recognized roles of u-PA as one of the major initiators of the matrix proteolysis cascade and as an activator of plasminogen and hepatocyte growth factor (HGF), we studied matrix degradation in liver shortly after partial hepatectomy. The activation of plasminogen to plasmin following partial hepatectomy was examined by Western blot analysis, and a small increase in plasmin at approximately 15 minutes followed by a large elevation at approximately 3 to 6 hours after partial hepatectomy was detected. In addition, we found that fibrinogen, the major substrate for plasmin, begins to be degraded at approximately 15 to 30 minutes following partial hepatectomy. Using immunohistochemical staining, we detected that the distribution of fibrinogen in normal liver is localized to the perisinusoidal space surrounding the periportal region. A decreased distribution of fibrinogen in the periportal region was found by 15 minutes and continued through 24 hours following partial hepatectomy. In addition, the distribution of fibronectin in normal liver was localized to the perisinusoidal space surrounding the periportal and the pericentral regions. A strikingly decreased distribution of fibronectin in the periportal region was found at 5 minutes after partial hepatectomy. Furthermore, we observed that the protein levels of laminin, entactin, and fibronectin in an extracellular matrix (ECM)-enriched preparation decreased shortly after partial hepatectomy, and were restored later. No changes were observed with either vitronectin or the integrin chain α(v). In contrast to the protein levels of the ECM components, the messenger RNA (mRNA) levels of fibronectin, integrin chain β1, and integrin chain αv gradually increased over 18 hours and then decreased thereafter. Taken together, these results suggest that rapid reorganization of selected ECM components are important for hepatocyte proliferation at the early stages of liver regeneration.
Methylcyclopentadienyl Manganese Tricarbonyl: Health Risk Uncertainties and Research Directions
Authors: J. Michael Davis
Journal: Environmental Health Perspectives (1998)

With the way cleared for increased use of the fuel additive methylcyclopentadienyl manganese tricarbonyl (MMT) in the United States, the issue of possible public health impacts associated with this additive has gained greater attention.In assessing potential health risks of particulate Mn emitted from the combustion of MMT in gasoline, the U.S. Environmental Protection Agency not only considered the qualitative types of toxic effects associated with inhaled Mn, but conducted extensive exposure-response analyses using various statistical approaches and also estimated population exposure distributions of particulate Mn based on data from an exposure study conducted in California when MMT was used in leaded gasoline.Because of limitations in available data and the need to make several assumptions and extrapolations, the resulting risk characterization had inherent uncertainties that made it impossible to estimate health risks in a definitive or quantitative manner.To support an improved health risk characterization, further investigation is needed in the areas of health effects, emission characterization, and exposure analysis.
How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19
Authors: Lu Tian, Jason L. Vassy, Christine Seel Ritchie, Chien-Chang Lee, Dae Hyun Kim
Journal: Annals of Internal Medicine (2021)

A. Cumulative incidence curves from ACTT-1 (Adaptive COVID-19 Treatment Trial) for the proportion of patients recovered, treating death as a competing risk and depicting days corresponding to the median recovery.B and C. Mean time in recovery, as the area under the cumulative incidence curve, across the 28 days of study follow-up.
NURSES AND MATRIMONY.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Comparison of effects of long-term carticotropin and corticosteroid treatment on responses of plasma growth hormone, ACTH, and corticoaterold to hypoglycaemiaDaly, J. R., Fletcher, M. R., Glass, D., Chambers, D. J., Bitensky, L., and Chayen, J.: Br. Med. J. 2: 521, 1974
Authors: None HF
Journal: Journal of Allergy and Clinical Immunology (1975)
Management of Unconscious Poisoned Patients
Authors: E. G. McQueen
Journal: BMJ (1969)

ITISHit cannot be too strongly emphasized that this study was not designed to discover varia- tions in intake levels of low statistical signi- ficance.Not only is Professor Yudkin's questionary too blunt an instrument for this, but interpretation of such circumstances is difficult because of statistical variation and the intrusion of minor variables, known and unknown The object, with no preconceived ideas to advance or defend, was to confirm or refute, with larger numbers and using a fairly " normal " population, Professor Yudkin's earlier finding of a very significant difference in sucrose intake between I.H.D. and control groups.Mean Sugar Intake (g.iweek) in 1,158 Controls and 170 I.H.D. Patients by Age Groupzng and Social Class Controls I.H.D.